Search
Now showing items 1-6 of 6
Trends in malaria case management following changes in the treatment policy to artemisinin combination therapy at the Mbakong Health Centre, Cameroon 2006-2012: a retrospective study
(Elsevier, 2015)
National malaria treatment policies are devised to guide health professionals and to facilitate diagnosis and case management. Following the recommendations of the WHO, Cameroon changed its malaria treatment policy from ...
Comparing antibody responses in chickens against Plasmodium falciparum lactate dehydrogenase and glyceraldehyde-3-phosphate dehydrogenase with Freund’s and Pheroid® adjuvants
(Taylor & Francis, 2015)
Pheroid® technology was assessed as an alternative to Freund’s adjuvant to raise antibodies in experimental animals. Chickens were immunized with two recombinantly expressed Plasmodium falciparum proteins, lactate dehydrogenase ...
Synthesis and in vitro biological evaluation of dihydroartemisinyl-chalcone esters
(Elsevier, 2015)
A series of dihydroartemisinyl-chalcone esters were synthesized through esterification of chalcones with dihydroartemisinin (DHA). The hybrids were screened against chloroquine (CQ) sensitive (3D7) and CQ resistant (W2) ...
The case for development of 11-aza-artemisinins for malaria
(Bentham Science, 2015)
The current treatment regimens for uncomplicated malaria comprise an artemisinin in combination with another drug (ACT). However, the recent emergence of resistance to ACTs in South East Asia dramatically emphasizes the ...
In vivo efficacy and bioavailability of lumefantrine: evaluating the application of Pheroid technology
(Elsevier, 2015)
The oral absorption of compounds with low aqueous solubility, such as lumefantrine, is typically limited by the dissolution rate in the gastro-intestinal tract, resulting in erratic absorption and highly variable ...
The potential use of natural and structural analogues of antimicrobial peptides in the fight against neglected tropical diseases + Erratum
(MDPI, 2015)
Recently, research into the development of new antimicrobial agents has been driven by the increase in resistance to traditional antibiotics and Emerging Infectious Diseases. Antimicrobial peptides (AMPs) are promising ...